Tilray Brands (NASDAQ:TLRY) Stock Price Down 2.7% – Should You Sell?

Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell 2.7% on Tuesday. The company traded as low as $3.25 and last traded at $3.27. Approximately 4,052,940 shares changed hands during trading, a decline of 4% from the average daily volume of 4,238,469 shares. The stock had previously closed at $3.36.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Portugal facility receives testing approval: Tilray Medical said Portugal’s INFARMED regulator authorized its Cantanhede facility to conduct microbiological and chemical/physical quality testing in-house under EU-GMP standards. The approval could reduce reliance on outside laboratories, shorten product-release timelines and support distribution into regulated international medical-cannabis markets. Tilray Medical Strengthens Global Medical Cannabis Supply Chain
• Neutral Sentiment: BrewDog is lifting reported revenue: Coverage of Tilray’s fiscal Q1 results noted that the acquired BrewDog beer operations contributed to revenue growth, while management expects the beer assets and international cannabis business to support future expansion. However, the acquisition’s contribution does not yet resolve broader profitability concerns. BrewDog Acquisition Boosts Tilray’s Stock Q1 Performance
• Negative Sentiment: Core cannabis performance weakened: Analysts highlighted that Q1 revenue growth was driven primarily by BrewDog, while cannabis revenue declined approximately 13%. Reports also described a disappointing revenue performance relative to expectations and a swing to an adjusted loss. Tilray Q1 Not Looking Good
• Negative Sentiment: Cash burn and dilution remain concerns: Tilray reportedly used $23.4 million in cash during the quarter, remained unprofitable and generated negative free cash flow. Shares outstanding increased more than 31% year over year, raising concern about shareholder dilution and the company’s path to sustainable earnings. Three Huge Red Flags From Tilray’s Q1 Earnings Report
• Negative Sentiment: Analyst caution adds pressure: At least one analyst reduced a price target, reinforcing investor concerns about declining cannabis sales, losses, cash usage and execution risks despite the company’s expansion initiatives. Tilray Analyst Price Target Cut

Analysts Set New Price Targets

A number of research firms have commented on TLRY. TD Cowen reduced their target price on Tilray Brands from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. TD Securities upgraded Tilray Brands to a “strong-buy” rating in a report on Friday, July 31st. Canaccord Genuity Group lowered their price target on Tilray Brands from $4.50 to $4.00 and set a “hold” rating for the company in a report on Friday. TD dropped their price target on Tilray Brands from $4.70 to $4.50 and set a “buy” rating on the stock in a research report on Monday, October 5th. Finally, Zacks Research cut Tilray Brands from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tilray Brands presently has a consensus rating of “Hold” and a consensus target price of $5.90.

Tilray Brands Stock Performance

The firm has a market capitalization of $445.37 million, a PE ratio of -2.34 and a beta of 1.91. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.88 and a quick ratio of 1.11. The firm has a fifty day moving average price of $4.26 and a 200 day moving average price of $4.99.

Tilray Brands (NASDAQ:TLRY) last released its earnings results on Tuesday, July 28th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.42). The business had revenue of $281.71 million for the quarter, compared to analysts’ expectations of $246.30 million. Tilray Brands had a negative net margin of 16.91% and a negative return on equity of 10.39%. Research analysts anticipate that Tilray Brands, Inc. will post -0.48 earnings per share for the current fiscal year.

Insider Transactions at Tilray Brands

In related news, CFO Carl Merton purchased 10,000 shares of Tilray Brands stock in a transaction on Tuesday, August 4th. The stock was purchased at an average cost of $4.62 per share, with a total value of $46,200.00. Following the acquisition, the chief financial officer directly owned 139,753 shares in the company, valued at approximately $645,658.86. This trade represents a 7.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders purchased 15,000 shares of company stock valued at $69,225. Company insiders own 1.60% of the company’s stock.

Institutional Trading of Tilray Brands

A number of large investors have recently bought and sold shares of TLRY. Integrated Wealth Concepts LLC acquired a new position in shares of Tilray Brands in the 2nd quarter worth approximately $27,000. Deutsche Bank AG acquired a new stake in Tilray Brands during the 2nd quarter valued at $44,000. Corient Private Wealth LP acquired a new stake in Tilray Brands during the 2nd quarter valued at $53,000. Essential Partners LLC increased its holdings in Tilray Brands by 110,137.5% during the 1st quarter. Essential Partners LLC now owns 8,819 shares of the company’s stock valued at $57,000 after purchasing an additional 8,811 shares in the last quarter. Finally, Centaurus Financial Inc. bought a new position in Tilray Brands in the 2nd quarter valued at $58,000. 9.35% of the stock is currently owned by institutional investors.

Tilray Brands Company Profile

Tilray Brands, Inc is a global consumer packaged goods company focused on cannabis, beverage alcohol, wellness and consumer products. The company develops, produces, distributes and markets a range of cannabis products, including dried flower, pre-rolls, vapes, edibles and medical cannabis products, subject to applicable regulations in the markets it serves.

Tilray also operates beverage alcohol businesses, including craft beer, spirits and other alcoholic beverages. Its portfolio has included brands such as SweetWater Brewing Company, Montauk Brewing Company and Breckenridge Distillery.